Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myeloma (MM) Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 New IND application for combination of felzartamab with

SHANGHAI and GAITHERSBURG, Md. , Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics, and ABL Bio, Inc.

SHANGHAI and GAITHERSBURG, Md. , Oct. 1, 2021 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in

The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021 The current U.S. NHL clinical trial has now expanded to include clinical sites in China as an international multi-center clinical trial, which will potentially lead to a

SHANGHAI and GAITHERSBURG, Md. , Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of China

SHANGHAI and GAITHERSBURG, Md. , Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE ESG

SHANGHAI and GAITHERSBURG, Md. , Sept. 2, 2021 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global

13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 Felzartamab

SHANGHAI and GAITHERSBURG, Md. , Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in

I-Mab received highest first-time ESG rating among China -based biotech companies from MSCI New majority independent ESG committee to set overall ESG strategies for the Company Women account for two-thirds of the total workforce and over 30% of I-Mab's Board of Directors Committed to diversity,